Navigation Links
BiPar Genomic Biomarker Data Demonstrate Overexpression of PARP-1 Gene in Multiple Cancer Types
Date:10/25/2007

SAN FRANCISCO, Oct. 25 /PRNewswire/ -- BiPar Sciences, Inc., a privately held biopharmaceutical company developing novel cancer therapies, today announced molecular biomarker data demonstrating the overexpression of the PARP (poly-ADP-ribose polymerase) protein in multiple cancers, including ovarian, breast and lung tumors. The research is the first demonstration of PARP overexpression in specific types of cancer. This insight is being used to guide the clinical development of the company's pipeline of PARP inhibitor candidates.

The results were presented at the American Association for Cancer Research-National Cancer Institute-European Organization for Research and Treatment of Cancer (AACR-NCI-EORTC) International Conference on Molecular Targets and Cancer Therapeutics in San Francisco.

"These results allow us to focus our clinical development plan for BSI-201 by targeting tumors types that have the greatest probability of clinical success," said BiPar Executive Vice President Barry Sherman, M.D.

BiPar researchers used the Gene Logic Inc. BioExpress(R) System database to analyze PARP-1 gene expression in all types of primary human cancer and compared the results to normal counterpart tissue. PARP expression was above the 95 percent upper confidence limit for normal tissue in ovarian cancer, intraductal breast cancer, lung cancer and uterine cancer. In contrast, prostate tumor tissue showed minimal PARP overexpression.

BSI-201 has been tested as both monotherapy and in combination with standard therapy in Phase 1 studies in patients with solid tumors. BiPar is preparing to initiate Phase 1b and Phase 2 trials of BSI-201 in several specific tumor types guided largely by gene expression data.

About PARP

PARP-1 plays a central role in cell proliferation and in DNA repair. BiPar's novel, proprietary PARP inhibitors are a new generation of drug candidates that show promising activity and a favorable toxicity profile. Preclinica
'/>"/>

SOURCE BiPar Sciences, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. Rosetta Genomics to Webcast Presentation at CE Unterberg, Towbin Emerging Growth Opportunities Conference
2. Rosetta Genomics and Weizmann Institute Scientists Identify Role of microRNA in Cancer Suppression
3. Introgen Reports Updated Phase 2 Advexin Data Correlating Improved Survival, Tumor Responses and Predictive p53 Biomarker
4. Pharmacyclics Identifies Functional Biomarkers for its Novel HDAC Inhibitor and Demonstrates Preclinical Anti-Tumor Activity with Brutons Tyrosine Kinase Inhibitors
5. Millennium Discovers Biomarkers Potentially Predictive of Response to Velcade (Bortezomib) for Injection
6. Introgen Presents ADVEXIN Biomarker Data at Major Cancer Conference
7. DNA Therapeutics Reports a Novel Mechanism of Action and a Biomarker of its Lead Molecule Dbait That Open an Innovative Pathway-Targeting in Molecular Cancer Therapy
8. Study Shows Ixabepilone Demonstrated Clear Activity in Patients with Metastatic Breast Cancer Resistant to Anthracycline, Taxane, and Capecitabine
9. The International Myeloma Foundation Says Data Reported at a Global Medical Meeting in Greece Demonstrates Improved Survival for a Wide Range of Myeloma Patients
10. Data Demonstrated Saxagliptin Added to Metformin Improved Glycemic Control in Subjects with Type 2 Diabetes Compared to Metformin Alone
11. Data Demonstrated Saxagliptin Added to Metformin Improved Glycemic Control in Subjects with Type 2 Diabetes Compared to Metformin Alone

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)....25/PRNewswire/-- ChemoCentryx,Inc.,announcedtoda...T-1(theProspectiveRandomizedOralTherapyEvaluationi...patientswithmoderate-to-severeCrohn,sdiseasedemons...abilityprofile.Thestudydemonstratedevidenceofclini...dasa70-pointdecreaseintheCrohn,sDiseaseActivityInd...
(Date:11/24/2009)...ewswire-FirstCall/--QuestDiagnosticsIncorporated(N...sting,informationandservices,announcedthatitissche...onferenceinNewYorkCity.Thepresentationisscheduledf..., Duringtheconference,thecompanywillreaffirmits...ingincometoexceed18%ofrevenues,anddilutedearningsp...
(Date:11/24/2009)...wswire/--Inadditiontofamily,friendsandhealth,cance...herThanksgivinggratitudelist. ,, "Theyheardthef...aidofMonday,sverdictstotaling$103millionindamagesa...2,000womennationwidewhohavesuedWyethandPfizerpharm...ndPrempro.Wisneskiandtheothervictimsofhormonethera...
Breaking Medicine Technology:ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 2ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 3ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 4ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 5Quest Diagnostics To Speak At The 21st Annual Piper Jaffray Healthcare Conference 2Maryland Woman Thankful for Wyeth Verdicts 2Ovarian Cancer Coalition Partners With Consuelo Vanderbilt Costin 56921 1Ovarian Cancer Coalition Partners With Consuelo Vanderbilt Costin 56921 2Air Quality Sciences Achieves Re Accreditation as the US Indoor Air Quality Testing Partner for Europes Coveted Blue Angel Program 56918 1Air Quality Sciences Achieves Re Accreditation as the US Indoor Air Quality Testing Partner for Europes Coveted Blue Angel Program 56918 2Air Quality Sciences Achieves Re Accreditation as the US Indoor Air Quality Testing Partner for Europes Coveted Blue Angel Program 56918 3AOBO Launches New OTC Product to Treat Throat Inflammation 14001 1AOBO Launches New OTC Product to Treat Throat Inflammation 14001 2
...al , AUSTIN, Texas--(BUSINESS WIRE)--May 30, 2007-...ed today the publication of,data describing the dr...n in a patient with a rare inherited form of cance...isorder characterized by,inherited mutations in th...orted treatment of Li-Fraumeni tumors with a thera...
...2007 - Gilead,Sciences, Inc. (Nasdaq:GILD) today a...udy of aztreonam lysine for inhalation for,the tre...e,pulmonary Pseudomonas aeruginosa (P. aeruginosa)...y 28 from baseline in respiratory,symptoms, as ass...,(CFQ-R), a patient-reported outcome (PRO) tool us...
Other Medicine Technology:Introgen's Advexin Demonstrates Clinical Benefit in Inherited,Cancer 2Introgen's Advexin Demonstrates Clinical Benefit in Inherited,Cancer 3Introgen's Advexin Demonstrates Clinical Benefit in Inherited,Cancer 4Gilead Announces Achievement of Primary Efficacy Endpoint in Second,Phase III Study of Aztreonam Lysine for Inhalation in Patients With,Cystic Fibrosis 2Gilead Announces Achievement of Primary Efficacy Endpoint in Second,Phase III Study of Aztreonam Lysine for Inhalation in Patients With,Cystic Fibrosis 3Gilead Announces Achievement of Primary Efficacy Endpoint in Second,Phase III Study of Aztreonam Lysine for Inhalation in Patients With,Cystic Fibrosis 4Gilead Announces Achievement of Primary Efficacy Endpoint in Second,Phase III Study of Aztreonam Lysine for Inhalation in Patients With,Cystic Fibrosis 5
(Date:11/27/2009)...SUR-SEINE,France,Nov.27/PRNewswire/--TeamGarmin-Sl...dicatedtoethicalsportinganddevelopingthenextgenera...omeTeamGarmin-TransitionswiththeadditionofTransiti...listheworld,sleadingmanufacturerofadaptiveeyewear,...widestselectionofspectaclelensessuchasTransitionsl...
(Date:11/27/2009)... bring unprecedented medical, economic burdens, st...Day News) -- The number of people with diabetes in...next 25 years, a new study predicts. , That wou...eople with the disease, up from 23.7 million today...ple with diabetes will triple, the study also warn...
(Date:11/27/2009)... Specialist manufacturers who use medical...ing millions of dollars by bringing in technology ...asing numbers of pro-active medical manufacturers ...ncept stage of their projects, ensuring that progr...cesses or potentially outdated technology. , ...
(Date:11/26/2009)... years, the number of Americans living with diabet...n in 2009 to 44.1 million in 2034. Over the same p...sing from $113 billion to $336 billion, even with ...ers based at the University of Chicago report in t...er of those with diabetes covered by Medicare will...
(Date:11/26/2009)... No more letters from the North Pole, Tex...ext messages from Santa , ...e operational efficiencies at the North Pole Santa...hildren all over the globe informed of his Christm...rsquo;s research department have identified a larg...
Breaking Medicine News(10 mins):Health News:Team Garmin-Slipstream Officially Re-named Team Garmin-Transitions With Addition of Transitions Optical as New Sponsor 2Health News:Team Garmin-Slipstream Officially Re-named Team Garmin-Transitions With Addition of Transitions Optical as New Sponsor 3Health News:Diabetes Cases Expected to Double in 25 Years 2Health News:Diabetes Cases Expected to Double in 25 Years 3Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 2Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 3Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 4Health News:Diabetes cases to double and costs to triple by 2034 2Health News:Diabetes cases to double and costs to triple by 2034 3Health News:Text Messages from Santa | Santa goes GREEN by going MOBILE for The March of Dimes 2
... 19 Clinical Information Network, Inc., the Video... LaBuda has joined its board of directors. , , Un...uda was the executive at Merck responsible for the... Customer Services. , , "Bob brings considerable ...
...lp the VH1 Save The Music Foundation restore music...emerging talent at premier music and film festival...bbott ( NYSE: ABT ) today announced that Zon...rumental music programs in America,s public school...
...o and con, has experts in a quandry , , T...of yesterday,s publication of two major studies on...t prostate cancer -- one finding that it didn,t sa...and Journal of Medicine , probably won,t end the l...
...if., March 19 Poniard Pharmaceuticals, Inc. (Nasd...on innovative oncology therapies, today announced ...present at the Needham & Company Cancer Therap...erview, including a discussion of the clinical dev...
...Wilson Chandler and Strength and Conditioning Coac...als, Award School with a ,got milk?, Get Fit Grant... Wilson Chandler along with strength and condition...y Finals . The new program is part of a new partn...
...arch 19 Based on its recent analysis of the field...livan recognizes Pioneer Surgical Technology, Inc....n of the Year Award for its development of the E-M...itable matrix for cell growth and differentiation ...
Other Medicine News:Health News:Former Merck Executive Joins Board of Clinical Information Network, Inc. 2Health News:Photo: ZonePerfect(R) Nutrition Bars Launches Nationwide Tour With VH1 Save The Music Foundation to Nourish Arts, America's Schools 2Health News:Photo: ZonePerfect(R) Nutrition Bars Launches Nationwide Tour With VH1 Save The Music Foundation to Nourish Arts, America's Schools 3Health News:Photo: ZonePerfect(R) Nutrition Bars Launches Nationwide Tour With VH1 Save The Music Foundation to Nourish Arts, America's Schools 4Health News:Photo: ZonePerfect(R) Nutrition Bars Launches Nationwide Tour With VH1 Save The Music Foundation to Nourish Arts, America's Schools 5Health News:Photo: ZonePerfect(R) Nutrition Bars Launches Nationwide Tour With VH1 Save The Music Foundation to Nourish Arts, America's Schools 6Health News:PSA Testing: What Should Men Do? 2Health News:PSA Testing: What Should Men Do? 3Health News:Poniard Pharmaceuticals to Present at Needham & Company's Cancer Therapeutics: Today & Tomorrow Conference 2Health News:Got Milk?(R) and the NBA Showcase New National Teen Health and Fitness Initiative at Democracy Prep Charter School 2Health News:Got Milk?(R) and the NBA Showcase New National Teen Health and Fitness Initiative at Democracy Prep Charter School 3Health News:Got Milk?(R) and the NBA Showcase New National Teen Health and Fitness Initiative at Democracy Prep Charter School 4Health News:Got Milk?(R) and the NBA Showcase New National Teen Health and Fitness Initiative at Democracy Prep Charter School 5Health News:Frost & Sullivan Lauds Pioneer Surgical Technology for Development of Tissue Scaffold E-Matrix 2Health News:Frost & Sullivan Lauds Pioneer Surgical Technology for Development of Tissue Scaffold E-Matrix 3Health News:Frost & Sullivan Lauds Pioneer Surgical Technology for Development of Tissue Scaffold E-Matrix 4
...ned to treat Achilles tendonitis and plantar fasci...der the foot arch and in back of the heel, the Air... to help reduce swelling and enhance circulation. ... and is simple to apply just slip it on like a so...
2360 SOFT FIT SUEDE FINISH WRIST BRACE
...bow brace has been designed by a team of medical s... motion. ,The SADER II Elbow/Forearm Brace has bee...with adjustable static and dynamic rotation forces...es, Post Surgical loss of Motion, Ulnar Osteotomy,...
XR Cubital Tunnel Elbow Splint
Medicine Products: